CME Credits
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Colorado School of Medicine and World Conference on Lung Cancer. The University of Colorado School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Colorado School of Medicine designates this live activity for a maximum of 27.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Certificates can be obtained from the CME Provider. Please contact Pam Welker at pam.welker@ucdenver.edu directly.
Who should attend?
The World Conference on Lung Cancer is designed for international physicians and researchers involved in the multidisciplinary clinical care of individuals with lung cancer. This audience includes medical, surgical, and radiation oncologists; pathologists; radiologists; and translational scientists. The World Conference may also be of benefit to other health care professionals involved in lung cancer-related clinical care or research. Patients and advocates can also attend and participate in a number of special programs design specifically to address their needs.
Needs Statement
Lung cancer is the leading cause of death worldwide. Despite intensive research efforts to discover more effective treatment regimens, the survival rates for lung cancer remain low. However, data from lung cancer research continue to emerge, with the identification of genetic mutations and the development of molecularly targeted agents that can help usher in the era of personalized lung cancer treatment. The World Conference on Lung Cancer provides a forum for the dissemination of the latest research findings to help physicians and researchers in lung cancer remain current on the optimum treatment approaches for individuals with lung cancer, as well as on issues related to prevention, early detection, imaging, staging according to the new IASLC staging system, and palliative care. The World Conference also addresses the importance of tobacco control in reducing the morbidity and mortality associated with lung cancer.
Official Language
The official language of the 14th World Conference on Lung Cancer is English.
Learning Objectives
After attending this conference, participants should be able to
- Analyze recent advances in prevention, imaging, and early detection of lung cancer
- Identify advances in the molecular biology and pharmacogenomics of lung cancer and their effect on personalized lung cancer treatment
- Apply the new IASLC staging system to thoracic malignancies
- Implement a therapeutic plan to include surgery, radiotherapy, systemic therapy or a combination of these based on stage, clinical and molecular features
- Interpret the results from recent clinical trials related to lung cancer, mesothelioma, and thymoma
- Define palliative care options for individuals with lung cancer
- Analyze the efficacy of tobacco control methods being used throughout the world
Unlabeled Usage Statement
The information presented at the World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
Programme Topics
The 14th World Conference on Lung Cancer will highlight recent important advances in lung cancer in the areas of prevention, early detection, molecular biology, biotechnology and therapy.